The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...

In addressing the fourth-quarter figures for Eylea three weeks earlier at the J.P. Morgan Healthcare Conference, Regeneron had hoped to shift the focus of its quarterly call to positive news ...

Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals (NASDAQ:REGN), and it's something market players shouldn't ignore. Our tracking of public options records ...